Icahn raised stake in Q2 from 6.3 to 6.8million shares.... also bough EMIS (new position).
The data from a 30 day clinical trial comparing Byetta to Extenade LAR show that Extenade is only mildly more effective than Byetta
Amylin CEO Dan Bradbury announces that 85% of diabetes specialists are recommending Byetta, and that this will likely lead to primary care physicians prescribing the treatment as well.